Cellular senescence mediates fibrotic pulmonary disease
Open accessThe DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index; 18 of the 31 sources its claims cite were checked for support.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by interstitial remodelling, leading to compromised lung function. Cellular senescence markers are detectable within IPF lung tissue and senescent cell deletion rejuvenates pulmonary health in aged mice. Whether and how senescent cells regulate IPF or if their removal may be an efficacious intervention strategy is unknown. Here we demonstrate elevated abundance of senescence biomarkers in IPF lung, with p16 expression increasing with disease severity. We show that the secretome of senescent fibroblasts, which are selectively killed by a senolytic cocktail, dasatinib plus quercetin (DQ), is fibrogenic. Leveraging the bleomycin-injury IPF model, we demonstrate that early-intervention suicide-gene-mediated senescent cell ablation improves pulmonary function and physical health, although lung fibrosis is visibly unaltered. DQ treatment replicates benefits of transgenic clearance. Thus, our findings establish that fibrotic lung disease is mediated, in part, by senescent cells, which can be targeted to improve health and function.
Overview
CoChat Summary
## TL;DR
This study links cellular senescence to idiopathic pulmonary fibrosis (IPF) by showing that senescence markers rise with disease severity in human lung tissue and that senescent fibroblast secretions are profibrotic. In a bleomycin mouse model, clearing senescent cells improved lung function and physical health, and dasatinib plus quercetin (DQ) reproduced the benefits of transgenic senescent-cell ablation.
## Key findings
- In human IPF lung samples, CDKN2A (p16) was significantly upregulated and increased with disease severity; higher pulmonary p16 expression correlated with reduced FVC, diffusion capacity, and SF-12 physical component score.
- In IPF tissue, p16-positive epithelial cells and fibroblasts were found in fibroblastic foci and honeycomb lung, and TAF-positive cells / γH2A.X foci were significantly increased relative to controls.
- In the bleomycin mouse model, lung injury increased whole-lung p16 expression by threefold, and SASP-related transcripts including Mcp1, Il6, Mmp12, Col1a1, and Tgfβ rose after bleomycin exposure.
- Senescent fibroblast conditioned medium was fibrogenic in vitro: it increased αSMA positivity to 62% vs 21% with control conditioned medium, increased traction forces, and induced fibrosis genes such as ACTA2, COL1A1, COL1A2, and FN1.
- In mice, senescent-cell clearance improved pulmonary/physical outcomes: Penh rose about twofold after bleomycin and was diminished by AP or DQ; lung compliance fell by 40% in vehicle-treated bleomycin mice but only 15% with AP or DQ; body weight loss averaged 3.6 g with vehicle vs about 1.6 g with AP/DQ; treadmill distance to exhaustion was >37% further with AP/DQ than vehicle.
- The paper states that histological fibrosis reductions did not reach statistical significance, despite functional benefits.
## Methods
- Human data came from LTRC control and IPF lung tissue samples, including microarray and RNA-seq datasets; the paper reports IPF n=27 and control n=10 for p16 immunohistochemistry, and transcriptome analyses stratified by FVC severity.
- The mouse study used male Ink-Attac mice given aerosolized intratracheal bleomycin (2 U/kg) or PBS, then randomized to AP20187, dasatinib plus quercetin (DQ), or vehicle at either an early prevention timepoint or a later treatment timepoint.
- Analyses included FACS of lung fibroblasts, epithelial cells, and endothelial cells, immunohistochemistry / immunofluorescence, conditioned-medium assays in IMR90 fibroblasts, traction force microscopy, RT-PCR, and statistical modeling with regression and multiple-comparison correction.
## Limitations
- The paper states that the bleomycin model spontaneously resolves, with resolution varying by factors such as genetic background and microbiome, which limits interpretation of late-stage effects.
- The authors state that they could not disentangle senescence-dependent from senescence-independent events governing fibrosis resolution.
- Lung fibrosis histology did not improve significantly after senescent-cell clearance, despite functional gains; the paper itself notes this may reflect the short time course and heterogeneity of the bleomycin model.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
13 Valid · 0 Not valid · 8 Not checked · 94 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Through secretion of the senescence-associated secretory phenotype (SASP), a broad repertoire of cytokines, chemokines, matrix remodelling proteases and growth factors, senescent cells paracrinely promote proliferation and tissue deterioration8.”
§ Cellular senescence mediates fibrotic pulmonary disease > Abstract
What the sources say
- Partly supportedcites [8] van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014). sourceExperimental — accuracy not yet measured
In “Senescence is a multi-step evolving process” (page unavailable), the paper says SASP-mediated paracrine signalling affects cell proliferation. In “Senescence in ageing and age-related disease” (page unavailable), it says SASP components are thought to promote proliferation of neoplastic cells and may intensify age-related tissue deterioration. The citing sentence presents those qualified effects as established and general. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Cellular senescence is an evolutionarily conserved state of stable replicative arrest induced by pro-ageing stressors also implicated in IPF pathogenesis, including telomere attrition, oxidative stress, DNA damage and proteome instability.”
§ Cellular senescence mediates fibrotic pulmonary disease > Abstract
What the sources say
- Partly supportedcites [8] van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014). sourceExperimental — accuracy not yet measured
The Abstract and 'Senescence is a multi-step evolving process' describe growth arrest, including a transition to stable cell-cycle arrest. 'Causes and effector pathways of senescence' identifies telomere erosion, DNA lesions, reactive oxygen species and proteotoxic stress as senescence-related stressors. The cited passages do not establish that senescence is evolutionarily conserved or that these stressors are implicated in IPF pathogenesis; the paper also distinguishes replicative senescence from other forms of senescence. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Critically, impaired capacity to resolve fibrotic bleomycin injury has been associated with accumulation of apoptosis-resistant, senescent myofibroblasts3.”
§ Cellular senescence mediates fibrotic pulmonary disease > Results > Senescent cell retention impairs fibrosis resolution Taken together, our in vivo results strongly support the hypothesis that elimination of senescent cells improves fibrotic pulmonary disease when treatment is initiated at the onset of pathogenesis. We next sought to test the clinically important question of whether senescent cell clearance provides comparable benefit when initiated at a timepoint when pathology has fully developed. Ink-Attac mice contained a strong senescent signature in lung fibroblasts and epithelial cells 2 weeks post-bleomycin challenge (Fig. 2), a timepoint of well-established fibrotic remodelling in the lung15. Accordingly, we administered a single dose of bleomycin or PBS through aerosolized intratracheal administration to Ink-Attac mice. Two weeks post challenge, we randomized bleomycin-exposed mice to AP, DQ or vehicle treatment groups based on change in body weight and non-invasively measured airway resistance (Penh). Mice were treated for 2 weeks and were killed 4 weeks following bleomycin or PBS exposure (Fig. 5a). Body weight monitoring revealed that, similar to our previous experiments (Fig. 4f), mice that received bleomycin lost substantial body mass, relative to mice that received PBS. Upon treatment initiation on day 14, mean body weight of mice treated with AP plateaued, while vehicle-treated, bleomycin-exposed counterparts continued to lose weight (Fig. 5a), suggestive of physical benefit afforded by senescent cell clearance, even when treatment is initiated in later-stage disease. Spontaneous resolution is an inherent limitation of the bleomycin IPF model, with the rate and variability of bleomycin-induced pathology resolution dependent on complex factors, including genetic background and the microbiome3839. Indeed, both endpoint compliance (Supplementary Fig. 6) and comparison of Penh airway resistance at endpoint (4 weeks post challenge) to measures taken at the treatment randomization timepoint (2 weeks post challenge) revealed appreciable, albeit variable, improvement in all bleomycin-exposed groups, including vehicle-treated mice, with AP-treated mice showing greatest improvement (Fig. 5b). Thus, in our hands, the 3–4-week-period following a single bleomycin exposure represents a pivotal window of natural resolution (Figs 4 and 5a,b). Critically, impaired capacity to resolve fibrotic bleomycin injury has been associated with accumulation of apoptosis-resistant, senescent myofibroblasts3. As we were unable to disentangle senescence-dependent and -independent events governing resolution, we queried whether p16 expression, a measure of senescent burden, was associated with indicators of disease persistence. Impaired lung function, as measured by endpoint airway resistance (Penh) (Fig. 5c) and airway compliance (Fig. 5d), correlated significantly with p16 transcript abundance. This finding is consistent with associations drawn in humans, in which increased p16 expression correlated significantly with reduced FVC, pulmonary diffusion capacity and physical function (Supplementary Fig. 1). Similarly, in bleomycin-exposed mice, expression of the inflammatory and fibrogenic SASP factors Mcp1 (Fig. 5e), Pai1 (Fig. 5f), Mmp10 (Fig. 5g) and Col1a1 (Fig. 5h) robustly correlated with p16 transcriptional activation. These results further support the notion that the presence and activities of senescent cells may dictate resolution capacity following bleomycin-induced pathology.
What the sources say
- Supportedcites [3] Hecker, L. et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci. Transl. Med. 6, 231ra247 (2014). source
The Introduction states that aged mice have impaired fibrosis resolution associated with senescent, apoptosis-resistant myofibroblasts. The Results identify bleomycin as the lung-injury model and report accumulation of senescent myofibroblasts in aged mice with persistent fibrosis. Page numbers are not provided in our copy. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescence was confirmed by expression profiling (p16, SASP factors) and/or SA-β-gal staining32 21 days post radiation.”
§ Cellular senescence mediates fibrotic pulmonary disease > Methods > Cell culture For experiments employing radiation-induced senescence, IMR90 (passages 5–7; ATCC, catalogue number CCL-186) and primary human fibroblasts (passages 3–6) were exposed to 10 Gy radiation or sham conditions using a RS2000 X-Ray Irradiator (RAD Source Technologies, Suwanee, GA). Normal bronchial epithelial cells (passages 4–7, Lot 7F3000, Lonza, Walkersville, MD) were exposed to 5 Gy or sham conditions. Senescence was confirmed by expression profiling (p16, SASP factors) and/or SA-β-gal staining32 21 days post radiation. For SA-β-gal staining, cells were fixed for 10 min in 2% formaldehyde+0.2% glutaraldehyde in PBS at room temperature. Cells were rinsed with PBS and incubated overnight in SA-β-gal staining solution containing the following: 1 mg ml−1 X-gal, 40 mM citric acid/sodium phosphate buffer pH 6.0, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM sodium chloride and 2 mM magnesium chloride in water. Cells were then rinsed in PBS and stored at 4 °C until imaging. Media applied 20 days post irradiation (or sham) was collected 24 h later and was diluted with NCM to reflect equivalent source cell concentrations. ProcartaPlex immunoassays (Affymetrix eBioscience) were used for CM secretome composition assessment, according to the manufacturer's specifications. Non-irradiated IMR90 cells (passages 5–7) were treated with NCM, NCM+2 ng ml−1 TGFβ, CCM or SASP-CM and applied to downstream analyses as indicated. Primary human fibroblasts collected from human patients were authenticated through αSMA staining. For senolytic treatment, sham and irradiated primary human fibroblasts were treated with indicated concentrations of DQ or navitoclax for 3 days, starting at day 20 post irradiation or sham exposure. Cell viability after drug treatment was measured by ATPLite Kits (PerkinElmer; Waltham, MA) performed according the manufacturer's instructions. Luminescence was read using a multi-scan plate reader (Fisher). For experiments utilizing etoposide-induced senescence, IMR90 human lung fibroblasts (passage 10; ATCC) were treated for 48 h with 20 μM etoposide (Enzo Life Sciences, Farmingdale, NY). Etoposide was removed and replaced with fresh media. Six days after etoposide removal, approximately 60% of IMR90 cells were SA-β-gal positive. Cells were treated for 48 h with 20 μM D+15 μM Q or 10 μM navitoclax (or untreated control) and the percentage of SA-β-gal-positive cells was determined using a C12FDG-based senescence assay described as follows46. Briefly, etoposide-treated senescent IMR90 cells were seeded at a concentration of 5 × 103 cells per well in 96-well plates 24 h before treatment. Following addition of the drugs, the cells were incubated for 48 h under 20% O2 oxygen conditions. For fluorescence analysis of SA-β-gal activity, cells were incubated for 1 h with 100 nM Bafilomycin A1 (Calbiochem, San Diego, CA). Next, 10 μM C12FDG (Setareh Biotech, Eugene, OR) was added to the culture medium and the cells were incubated for 1.5–2 h. Ten minutes before analysis, the DNA intercalating Hoechst dye (2 μg ml−1) was added to the cells. For quantitative analysis of cell number (Hoechst staining) and number of C12FDG-positive senescent cells, a laser-based line scanning confocal imager IN Cell 6000 Analyzer was used. All samples were analysed in duplicate with three to five fields per well.
What the sources say
- Partly supportedcites [32] Baker, D. J. et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530, 184–189 (2016). sourceExperimental — accuracy not yet measured
In “ATTAC clears senescent adipocyte progenitor cells” (page unavailable), the paper identifies cells using p16 expression, other senescence markers, and SAβ-Gal staining. It studies naturally occurring senescent cells, however, and does not support the claim’s 21-day post-radiation condition. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, CM collected from irradiated bronchiolar epithelial cells did not activate a fibrogenic response, as measured by αSMA fibrotic activation of naive IMR90 cells (Supplementary Fig. 2), suggesting that cell-type-specific SASP composition may differentially affect pathological phenotypes within the lung.”
§ Cellular senescence mediates fibrotic pulmonary disease > Results > The secretome of senescent fibroblasts is profibrotic
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
61 more claims
Create a free account to see all 115 claims and to verify the 5 references still open.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 26
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is in agreement with a recent report showing that the removal of senescent cells expressing high levels of p16INK4a can lead to fibrosis in mice101, whereas small-molecule senolytics appear to reduce fibrosis in several mouse tissues22,71,73,75,102.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in a mouse model of idiopathic pulmonary fibrosis (IPF), D + Q treatment improved lung compliance and reduced frailty71.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with IPF accumulate TAFs and senescence markers in lungs that increase with disease severity and activate SASP52.”
From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of various natural flavonoids, including quercetin and fisetin, either alone or in combination with dasatinib, a pan-tyrosine kinase inhibitor, can stimulate senolysis in a variety of contexts in vitro and in vivo199,207–210.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“consistent with enhanced paracrine signaling from increased numbers of senescent neighbors and with established features of epithelial aging.23,25,32–35”
From SenCat: Cataloging human cell senescence through multi-omic profiling of multiple senescent primary cell types (2026) · cites this paper as [33]
Experimental — accuracy not yet measured
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670
Self-citationNaturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876 · cited 2×
“Attenuation of age-related pathologies and extension of lifespan in chronologically aged mice has been demonstrated using the same transgenic strategy 32–34 , and improvements in lung structure and function in aged mice have recently been demonstrated using a similar suicide-gene strategy 20 .”
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
The role of senescent cells in ageing
van Deursen, J. M. (2014) · Nature · doi:10.1038/nature13193 · Cited by 2,623
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584 · cited 2×
“An alternative approach to transgenic senescent cell clearance is senolytics 21,22 , which may be a tractable treatment option for humans.”
Self-citationDesmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA
Demaria, M., Ohtani, N., Youssef, S. A., Rodier, F., Toussaint, W., Mitchell, J. R., Laberge, R.-M., Vijg, J., Van Steeg, H., Dollé, M. E. T., et al. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.11.012 · Cited by 2,045
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Cited by
Items 901–1,000 of 1,619
Exploring Novel Therapeutics for Pulmonary Arterial Hypertension: From the Bench to the Bedside
Fujiwara, T., Ishii, S., Minatsuki, S., Hatano, M., & Takeda, N. (2025) · International Heart Journal · doi:10.1536/ihj.24-615 · Cited by 11
Comprehensive Bioinformatics Identifies Key microRNA Players in ATG7-Deficient Lung Fibroblasts
Stojanović, S. D., Fuchs, M., Fiedler, J., Xiao, K., Meinecke, A., Just, A., Pich, A., Thum, T., & Kunz, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114126 · Cited by 13
“This includes IPF, where senescent cells showed a pro-inflammatory and pro-fibrotic phenotype [27,29,30].”
BackgroundNAD + , Senolytics, or Pyruvate for Healthy Aging?
Zhou, F. (2021) · Nutrition and Metabolic Insights · doi:10.1177/11786388211053407 · Cited by 12
Keow, J. Y., Cecchini, M. J., Jayawardena, N., Zompatori, M., JOSEPH, M. G., & Mura, M. (2022) · Respiratory Research · doi:10.1186/s12931-022-02067-w · Cited by 17
“The induction of cellular senescence in these cases of pulmonary fibrosis may be mediated by p16 activation [18, 19], arresting the cell cycle through activation of this retinoblastoma-mediated CDK 4/6 pathway.”
BackgroundLino, C. A., Silva, T. D. O., Lunardon, G., Balbino-Silva, C., Lima, V. M., Huang, Z.-P., Donato, J., Takano, A. P. C., Barreto‐Chaves, M. L. M., Wang, D., et al. (2023) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111775 · Cited by 12
Senescence and autophagy in usual interstitial pneumonia of different etiology
Gallob, F., Brčić, L., Eidenhammer, S., Rumpp, F., Nerlich, A., & Popper, H. (2020) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-020-02917-2 · Cited by 13
Treating Senescence like Cancer: Novel Perspectives in Senotherapy of Chronic Diseases
Mongelli, A., Atlante, S., Barbi, V., Bachetti, T., Martelli, F., Farsetti, A., & Gaetano, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217984 · Cited by 13
“To further explore the effect of D + Q, the combination was tested on human fetal lung fibroblast (IMR90), and it has been observed that the administration of D + Q increased the clearance of senescent cells [107].”
BackgroundMethodInfluentialTakahashi, T., & Schleimer, R. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111709 · Cited by 16
“Accumulation of senescent epithelial cells has also been observed in fibrotic disorders in lung and kidney and accelerated senescence is speculated to be crucial for the initiation and progression of fibrosis in these diseases [128,129].”
BackgroundDoan, L., Paine, P., Tran, C., Parsons, B., Hiller, A., Joshua, I., Collaco, N., Vitari, A., de Morrée, A., Ishak, H. D., et al. (2020) · doi:10.21203/rs.3.rs-92962/v1 · Cited by 16
Chen, X., Wu, F., Chen, C., Ren, Q., & Zhang, A. (2024) · Biological Trace Element Research · doi:10.1007/s12011-023-04021-3 · Cited by 11
“Moreover, the accumulation of senescent hepatocytes can reduce liver physiological function and is associated with the development of multiple liver injury-related diseases [6–8].”
Jin, M., Li, C., Wu, Z., Tang, Z., Xie, J., Wei, G., Yang, Z., Huang, S., Chen, Y., Li, X., et al. (2025) · Advanced Science · doi:10.1002/advs.202414830 · Cited by 17
Baker, J. R., Daly, L., Hassibi, S., Kimura, G., Nishimoto, Y., Kizawa, Y., & Ito, K. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1451056 · Cited by 17
Grafanaki, K., Maniatis, A., Sotiropoulou, V., Pasmatzi, E., & Τzouvelekis, Α. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178394 · Cited by 16
“Additionally, senolytic agents such as navitoclax (a Bcl-2 family inhibitor) and flavonoid fisetin clear senescent fibroblasts in both IPF and cutaneous fibrosis models [98,327–329].”
Morciano, G., Pellielo, G., Agyapong, E. D., Pellegrino, C., Patergnani, S., Franceschini, D., Koutsikos, K., Rigon, L., Pinton, P., & Rimessi, A. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07783-1 · Cited by 20
“This phenotype is accompanied by elevated expression of the cyclin-dependent kinase inhibitor CDKN2A, which correlates with disease severity [177] and by down-regulation of PINK1 and Parkin, leading to defective mitophagy [154, 155, 178].”
Senescence in cancer: Hallmarks, paradoxes, and therapeutic promise
Hinterleitner, C., Goldberg, H. V., McHugh, D., Barthet, V. J. A., Filliol, A. A., & Lowe, S. W. (2026) · Cell · doi:10.1016/j.cell.2026.03.005 · Cited by 23
“Through the SASP, senescent cells can promote immune-mediated clearance of damaged or premalignant cells or, when persistent, drive chronic inflammation, fibrosis, and tumor progression 10,17,65,66 .”
InfluentialThe role of RNA helicases in aging and lifespan regulation
Park, S., Park, H. H., Son, H. G., & Lee, S. (2017) · Translational Medicine of Aging · doi:10.1016/j.tma.2017.08.001 · Cited by 12
Kang, J., Yang, M.-S., Kim, D., & Park, C. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2149899 · Cited by 13
“The average patient survival is 3–5 years after diagnosis because the disease has a poor prognosis (Hopkinson et al., 2012; Johanson and Sonnenberg, 1990; Schafer et al., 2017).”
BackgroundIL-1 and senescence: Friends and foe of EGFR neutralization and immunotherapy
Romaniello, D., Gelfo, V., Pagano, F., Sgarzi, M., Morselli, A., Girone, C., Filippini, D. M., D’Uva, G., & Lauriola, M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1083743 · Cited by 15
“Thus, the contemporary targeting of senescence by senotherapeutic drugs along with target therapy toward ERBB family members may boost the efficacy of future cancer treatment (Zhu et al., 2015; Schafer et al., 2017; Ovadya and Krizhanovsky, 2018; Romaniello et al., 2022).”
BackgroundSenomorphic effect of diphenyleneiodonium through AMPK/MFF/DRP1 mediated mitochondrial fission
Liao, K.-M., Chen, C., Luo, W., Hsu, C.-W., Yu, S., Yang, P., & Su, K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114616 · Cited by 11
Purinergic signaling promotes premature senescence
Volonté, D., Benson, C. J., Daugherty, S. L., Beckel, J. M., Trebak, M., & Galbiati, F. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107145 · Cited by 17
Lin, X., Zhang, K., Liu, K., Liu, K., Sun, Y., Wu, W., Liu, K., Yi, X., Wang, X., Qu, Z., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176631 · Cited by 14
ZNF469 is a profibrotic regulator of extracellular matrix in hepatic stellate cells
Ariyachet, C., Nokkeaw, A., Boonkaew, B., & Tangkijvanich, P. (2024) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30578 · Cited by 13
Spina, J. S., Carr, T. L., Phillips, L. A., Knight, H., Crosbie, N. E., Lloyd, S. M., Jhala, M. A., Lam, T. J., Kármán, J., Clements, M. E., et al. (2024) · Aging · doi:10.18632/aging.205994 · Cited by 13
Huo, C., Jia, Q., Jiao, X., Jiang, Q., Zeng, X., Zhang, J., Wang, Y., Zhu, Z., & Tian, L. (2025) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2025.138238 · Cited by 15
Insights Into Effects of Natural Bioactive Components on Inflammatory Diseases in Respiratory Tract
Luo, J., Luo, J., Fang, Z., Fu, Y., & Xu, B. (2025) · Phytotherapy Research · doi:10.1002/ptr.8367 · Cited by 16
“Specifically, natural components that can improve airway inflammation contain resveratrol (Donnelly et al. 2004) and quercetin from Vitis vinifera (Donnelly et al. 2004; Hohmann et al. 2019; Schafer et al. 2017), and melanin from milk (Kim et al. 2012).”
InfluentialKawaguchi, K., Asai, A., Mikawa, R., Ogiso, N., & Sugimoto, M. (2022) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.22-0109 · Cited by 12
Bmal1-deficient mouse fibroblast cells do not provide premature cellular senescence in vitro
Nakahata, Y., Yasukawa, S., Khaidizar, F. D., Shimba, S., Matsui, T., & Bessho, Y. (2018) · Chronobiology International · doi:10.1080/07420528.2018.1430038 · Cited by 14
“© 2018 Taylor & Francis Group, LLC progression of already established age-associated disorders and extends median lifespan (Baar et al. 2017; Baker et al. 2016; Chang et al. 2016; Schafer et al. 2017; Hashimoto et al. 2016; Yosef et al. 2016).”
BackgroundThe ING1a model of rapid cell senescence
Bertschmann, J., Thalappilly, S., & Riabowol, K. T. (2018) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2018.06.004 · Cited by 14
The STATus of STAT3 in Lung Cell Senescence?
Adnot, S., Lipskaia, L., & Bernard, D. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0013ed · Cited by 11
“Targeting cell senescence may hold therapeutic promise in these diseases (4, 5).”
New Insights into Chronological Mobility of Retrotransposons In Vivo
Ghanam, A. R., Cao, J., Ouyang, X., & Song, X. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/2818415 · Cited by 10
“Discussion Data accumulated in the last 30 years have helped us to identify different environmental and genetic factors, as well as chemical substances that affect lifespan in many different eukaryotic species [32, 33].”
BackgroundAntoniou, K. M., Tsitoura, E., Vasarmidi, E., Symvoulakis, E. K., Aidinis, V., Tzilas, V., Τzouvelekis, Α., & Bouros, D. E. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.12.007 · Cited by 12
Alexa‐Stratulat, T., Tanasa, M. P., Cianga, V. A., & Antoniu, S. A. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2139242 · Cited by 13
Idiopathic Pulmonary Fibrosis: Cell Death and Inflammation Revisited
Saux, C. J. L., & Chapman, H. A. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0083ed · Cited by 12
Endometrial Stromal Senescence Mediates the Progression of Intrauterine Adhesions
Deryabin, P. I., & Borodkina, A. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094183 · Cited by 11
“Current research indicates that senescent cells directly contribute to the development of fibrotic diseases through profibrogenic factors present in the SASP, notably transforming growth factor beta (TGF-β ), interleukin-11 (IL-11), and SERPINE1 [9–11].”
Translating cellular senescence research into clinical practice for metabolic disease
Chaib, S., Palmer, A. K., Wyles, S. P., Musi, N., Kirkland, J. L., & Tchkonia, T. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01187-9 · Cited by 18
“Notably, DNAm GrimAge correlates highly with the blood biomarkers plasminogen activator inhibitor 1, tissue inhibitor metalloproteinase 1 and growth differentiation factor 15, which are also part of the SASP and are produced by senescent cells 6,7,172,175,179,180 .”
InfluentialSelf-citationZeng, X., Li, J., Wang, J., Zhang, J., Wang, Y., Wang, Y., Wang, Y., Tian, L., & Zhu, Z. (2025) · Aging Cell · doi:10.1111/acel.70275 · Cited by 10
“Growing evidence highlights its pivotal role in fibrotic lung diseases (Schafer et al. 2017).”
Idiopathic Pulmonary Fibrosis: Cellular Heterogeneity, Mechanisms, and Therapeutic Implications
Zuo, L., Liu, Q., Ye, D., Fan, J., & Wu, L. (2025) · MedComm · doi:10.1002/mco2.70521 · Cited by 21
Induction of Senescence by Loss of Gata4 in Cardiac Fibroblasts
Zhang, Z., Shayani, G., Xu, Y., Kim, A., Hong, Y., Feng, H., & Zhu, H. (2023) · Cells · doi:10.3390/cells12121652 · Cited by 10
“Importantly, cellular senescence has been shown to play important roles in fibrotic wound repair processes in multiple tissues, including the liver [9], skin [10,11], lung [12], heart [13–16], and spinal cord [17].”
BackgroundZhang, Y., Hu, G., Zhang, Q., Hong, S., Su, Z., Wang, L., Wang, T., Yu, S., Yuan, F., Zhu, X., et al. (2024) · Environmental Pollution · doi:10.1016/j.envpol.2024.123947 · Cited by 12
Fibroblast senescence-associated extracellular matrix promotes heterogeneous lung niche
Howes, A. M., Dea, N. C., Ghosh, D., Krishna, K., Wang, Y., Li, Y., Morrison, B., Toussaint, K. C., & Dawson, M. (2024) · APL Bioengineering · doi:10.1063/5.0204393 · Cited by 17
Aging in chronic lung disease: Will anti-aging therapy be the key to the cure?
Wang, W., Zhou, K., Wang, L., Qin, Q., Liu, H., Qin, L., Yang, M., Yuan, L., & Liu, C. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176846 · Cited by 10
Zhou, Y., Su, W., Xu, M.-Z., Zhang, A., Li, S., Guo, H., Gong, K., Lu, K., Yu, X., Zhu, Q., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119568 · Cited by 10
Takashima, T., Zeng, C., Murakami, E., Fujiwara, N., Kohara, M., Nagata, H., Feng, Z., Sugai, A., Harada, Y., Ichijo, R., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.187172 · Cited by 12
“19, and GSE124685, ref.”
Brügger, M., Machahua, C., Zumkehr, T., Cismaru, C. V., Jandrasits, D., Trüeb, B. S., Ezzat, S., Esteves, B. I. O., Dorn, P., Marti, T. M., et al. (2025) · Respiratory Research · doi:10.1186/s12931-025-03190-0 · Cited by 13
“Expression levels for the genes of interest were normalized to the housekeeping genes 18S ribosomal RNA (rRNA) or beta-2-microglobuline (B2M) [33, 38–47].”
Chen, Y., Huang, H., Luo, Y., Wu, H., Deng, W., Min, X., Lao, H., & Xiong, H. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156772 · Cited by 13
Namba, S., Iwata, M., Nureki, S., Otani, N. Y., & Yamanishi, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-58464-4 · Cited by 12
“Finally, we validated the predicted activatory targets using an independent resource, an IPF cohort (19 IPF and 18 healthy donors) from the Lung Tissue Research Consortium 37 (Supplementary Meth-ods).”
Wu, J., Zhang, L., Zhao, Z., Liu, Y., Li, Z., Feng, X., Zhang, L., Yao, X., Du, J., Chen, L., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102783 · Cited by 10
Chiche, A., Djoual, L., Charifou, E., Wang, S., Temime, L., Saclier, M., Wang, S., Chantrel, J., & Li, H. (2026) · Nature Aging · doi:10.1038/s43587-025-01058-y · Cited by 12
Targeted Therapeutics Delivery by Exploiting Biophysical Properties of Senescent Cells
Low, J., Chan, B., & Tay, A. K. P. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202107990 · Cited by 11
Emerging therapeutic targets in systemic sclerosis
O’Reilly, S. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02424-w · Cited by 10
“Studies have indicated that pulmonary fibrosis is mediated by senescent cells [135] and associated with various SASP components.”
Therapeutic Strategies for Idiopathic Pulmonary Fibrosis – Thriving Present and Promising Tomorrow
Gupta, N., Paryani, M., Patel, S. S., Bariya, A. H., Srivastava, A., Pathak, Y. V., & Butani, S. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2408 · Cited by 11
Robbins, P. D., & Niedernhofer, L. J. (2017) · Aging Cell · doi:10.1111/acel.12620 · Cited by 12
“…senolytics include the tyrosine kinase inhibitor Dasatinib (D), the flavonoid Quercetin (Q), the Bcl-2 family inhibitor Navitoclax, piperlongumine and Hsp90 inhibitors (Zhu et al., 2015; Chang et al., 2016; Wang et al., 2016; Zhu et al., 2016; Schafer et al., 2017; Zhu et al., 2017; Paul Robbins).”
BackgroundSelf-citationProcancerogenic activity of senescent cells: A case of the peritoneal mesothelium
Mikuła‐Pietrasik, J., Stryczyński, Ł., Uruski, P., Tykarski, A., & Książek, K. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.01.002 · Cited by 11
“…intervertebral disc degeneration (Le Maitre et al., 2007), macular degeneration (Marazita et al., 2016), chronic obstructive pulmonary disease (Noureddine et al., 2011), fibrotic pulmonary disease (Schafer et al., 2017), hepatic steatosis (Ogrodnik et al., 2017), and cancer (Lecot et al., 2016).”
BackgroundOno, M., Kobayashi, S., Hanagama, M., Ishida, M., Sato, H., Makiguchi, T., & Yanai, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239764 · Cited by 10
“Tobacco smoking induces alveolar epithelial cellular senescence, which is a state of replicative arrest brought on by cellular stressors, including tobacco smoke, and results in the emergence of the senescence-associated secretory phenotype [28].”
BackgroundPartial recovery of senescence in circulating follicular helper T cells after Dasatinib treatment
Talepoor, A. G., Khosropanah, S., & Doroudchi, M. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107465 · Cited by 10
Identification of Genetic Signature Associated With Aging in Pulmonary Fibrosis
Lu, Y., Chen, J., Wang, S., Tian, Z., Fan, Y., Wang, M., Zhao, J., Tang, K., & Xie, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.744239 · Cited by 11
“Moreover, biomarkers of aging, including p21 and p16, are also found significantly upregulated in both epithelial cells and fibroblasts in lung tissue of patients with IPF as compared with that of healthy people (8).”
BackgroundPark, M., Na, J., Kwak, S. Y., Park, S., Kim, H., Lee, S., Jang, W., Lee, S. B., Jang, W. I., Jang, H., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158390 · Cited by 13
“Recent reports demonstrated that senescence-associated LT release drives pulmonary fibrosis, eliminating senescent cells ameliorates these effects [10,22], and that the synthesis of PG is essential to reinforce senescence-associated cell cycle arrest [23].”
BackgroundCai, Z., Wang, H., Hu, J., Qu, C., Chen, S., Liu, X., & Fan, C. (2025) · The American Journal of Sports Medicine · doi:10.1177/03635465251381763 · Cited by 12
“10,30,34 Notably, although interventions targeting cellular senescence, such as exosome-based therapies, have shown potential in improving rotator cuff healing, studies on senolytics in rotator cuff injuries remain scarce, with only a single ex vivo experiment demonstrating that DQ reduces…”
Tripathi, U., Suda, M., Kulshreshtha, V., Piatkowski, B. T., Palmer, A. K., Giorgadze, N., Inman, C. L., Gasek, N. S., Xu, M., Johnson, K. O., et al. (2025) · Aging Cell · doi:10.1111/acel.70358 · Cited by 11
Self-citationMatsubayashi, S., Ito, S., Araya, J., & Kuwano, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1079626 · Cited by 15
“A similar benefit was achieved by administering D + Q (78).”
BackgroundMethodWang, Q., Li, A., Li, Q., Li, Q., Wang, Q., Wu, S., Meng, J., Liu, C., Wang, D., & Chen, Y. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176843 · Cited by 11
Senescent lung-resident mesenchymal stem cells drive pulmonary fibrogenesis through FGF-4/FOXM1 axis
Liu, Y., Ji, J., Zheng, S., Wei, A., Li, D., Shi, B., Han, X., & Chen, X. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03866-2 · Cited by 10
“Recently, cellular senescence has been demonstrated to be essential in contributing fibrotic lung diseases and can be targeted to improve pulmonary function [6].”
BackgroundConvergent evolution of senescent fibroblasts in fibrosis and cancer with aging
Lee, J. Y., & Peng, T. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.10.002 · Cited by 14
The Hippo Signaling Pathway Manipulates Cellular Senescence
Miyajima, C., Nagasaka, M., Aoki, H., Toriuchi, K., Yamanaka, S., Hashiguchi, S., Morishita, D., Aoyama, M., Hayashi, H., & Inoue, Y. (2024) · Cells · doi:10.3390/cells14010013 · Cited by 11
“Senescence biomarkers, such as Ki-67 and p16, have been detected in human IPF, suggesting a pathological role for aging in this disease [70,71].”
Ginsenoside Rb1 Relieves Cellular Senescence and Pulmonary Fibrosis by Promoting NRF2/QKI/SMAD7 Axis
Zheng, Q., Lei, F.-P., Hui, S., Tong, M., & Liang, L.-H. (2024) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x24500952 · Cited by 9
Lian, W., Cheng, D., Sun, W., Wang, T., Jia, X., Jia, Z., Liu, Y., & Ni, C. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.117917 · Cited by 10
Radiation-Induced Brain Injury with Special Reference to Astrocytes as a Therapeutic Target
Wang, C., Fan, X., Shi, Y., & Tang, F. R. (2025) · Journal of Integrative Neuroscience · doi:10.31083/jin25907 · Cited by 12
Aging-dependent YAP1 reduction contributes to AD pathology by upregulating the Nr4a1-AKT/GSK-3β axis
Lei, L., Cheng, Y., Yin, A., Han, J.-M., Wu, G., Yang, F., Wang, Q., Wang, J., Liu, R., Li, H., et al. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00487-4 · Cited by 17
Cell‐Surface LAMP1 is a Senescence Marker in Aging and Idiopathic Pulmonary Fibrosis
Meca-Laguna, G., Qiu, M., Hou, Y., Barkovskaya, A., Shankar, A., Dixit, B., Rae, M. J., Boominathan, A., & Sharma, A. (2025) · Aging Cell · doi:10.1111/acel.70141 · Cited by 11
“An increase in the expression of SA- β-Gal, p16, or p21 in the lungs of mice treated with BLM is also well documented (Biran et al. 2017; Schafer et al. 2017).”
InfluentialTanner, L., Bergwik, J., Single, A., Bhongir, R. K. V., Erjefalt, J. S., & Egesten, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.899469 · Cited by 10
“Whilst recent efforts have focused on removal of senescent or damaged fibroblasts (David et al., 2017; Schafer et al., 2017), our approach advantageously suppresses pro-fibrotic mediators and immune cell recruitment with reduced cytotoxicity.”
BackgroundIn vitro and in vivo toxicity assessment of the senotherapeutic Peptide 14
Zonari, A. A. C., Brace, L. E., Alencar‐Silva, T., Porto, W. F., Foyt, D. A., Guiang, M., Cruz, E. A. O., Franco, O. L., Oliveira, C. R., Boroni, M., et al. (2022) · Toxicology Reports · doi:10.1016/j.toxrep.2022.07.018 · Cited by 9
Exploiting the potential of lung stem cells to develop pro-regenerative therapies
Hynds, R. E. (2022) · Biology Open · doi:10.1242/bio.059423 · Cited by 11
“Promisingly, removal of senescent cells from the lungs using either genetic ablation or treatment with senolytic drugs, such as dasatinib and quercetin, can restore stem cell markers and improve lung function in experimental models of both pulmonary fibrosis (Lehmann et al., 2017; Schafer et al., 2017) and COPD (Ganes…”
BackgroundKRT5+/p63+ Stem Cells Undergo Senescence in the Human Lung with Pathological Aging
Moreno‐Valladares, M., Moncho-Amor, V., Silva, T. M., Garcés, J. P., Álvarez‐Satta, M., & Matheu, A. (2023) · Aging and Disease · doi:10.14336/ad.2022.1128 · Cited by 8
“In addition, increased p16 expression correlates with the severity of disease in patients [26, 27].”
BackgroundUBQLN1 deficiency mediates telomere shortening and IPF through interacting with RPA1
Zhou, H., Xie, C., Xie, Y., He, Y., Chen, Y., Zhang, C., Zhang, Y., Zhao, Y. B., & Liu, H. (2023) · PLoS Genetics · doi:10.1371/journal.pgen.1010856 · Cited by 8
“Idiopathic pulmonary fibrosis (IPF) is an age-related disease with unknown etiology but at least partially due to accumulated senescent cells in the tissue [30], and the patients’ survival rate is correlated with telomere length [31].”
BackgroundVelázquez-Enríquez, J. M., Reyes-Avendaño, I., Santos-Álvarez, J. C., Reyes-Jiménez, E., Vásquez-Garzón, V. R., & Baltiérrez‐Hoyos, R. (2023) · Advances in respiratory medicine · doi:10.3390/arm91050032 · Cited by 11
Brand, M., Ritzmann, F., Kattler, K., Milasius, D., Yao, Y., Herr, C., Kirsch, S. H., Müller, R., Yildiz, D., Bals, R., et al. (2024) · Respiratory Research · doi:10.1186/s12931-023-02636-7 · Cited by 12
Senotherapeutics and HIV-1 Persistence
Szaniawski, M. A., & Spivak, A. M. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-020-00496-0 · Cited by 9
Diagnostic and Therapeutic Applications of Extracellular Vesicles in Interstitial Lung Diseases
Ibrahim, A., Ibrahim, A., & Parimon, T. (2021) · Diagnostics · doi:10.3390/diagnostics11010087 · Cited by 11
“Another principal driving pathway in lung fibrosis is cellular senescence [77,78].”
BackgroundStojanović, S. D., Fuchs, M., Liang, C., Schmidt, K., Xiao, K., Just, A., Pfanne, A., Pich, A., Warnecke, G., Braubach, P., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-89531-7 · Cited by 10
Prašnikar, E., Perdih, A., & Borišek, J. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00414 · Cited by 11
The dual distinct role of telomerase in repression of senescence and myofibroblast differentiation
Harada, M., Hu, B., Lu, J., Wang, J., Rinke, A. E., Wu, Z. B., Liu, T., & Phan, S. H. (2021) · Aging · doi:10.18632/aging.203246 · Cited by 10
“We examined next the effects of hydrogen peroxide (H2O2) induced cellular senescence, and possible concomitant myofibroblast differentiation [47].”
BackgroundMultiwalled Carbon Nanotubes Induce Fibrosis and Telomere Length Alterations
Alswady‐Hoff, M., Erdem, J. S., Aleksandersen, M., Anmarkrud, K. H., Skare, Ø., Lin, F. ‐., Simensen, V., Arnoldussen, Y. J., Skaug, V., Ropstad, E., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116005 · Cited by 9
“Cellular senescence is known for contributing to aging and tumour suppression, but in recent years, it has also been implicated in several pathological processes, including tumour promotion and lung fibrotic disease [12,43,44].”
BackgroundNosrati, F., Grillari, J., Azarnia, M., Nabiuni, M., Moghadasali, R., Karimzadeh, L., & Lämmermann, I. (2023) · Biogerontology · doi:10.1007/s10522-022-10013-y · Cited by 12
“The expression of several fibrosis genes was elevated in non-senescent human IMR90 cells treated with media conditioned by senescent cells when compared to the control groups (Schafer et al. 2017).”
BackgroundIPF and CPFE—The Two Different Entities or Two Different Presentations of the Same Disease?
Kwiatkowska, S. (2017) · Advances in respiratory medicine · doi:10.5603/arm.a2017.0049 · Cited by 8
“Moreover, in the murine model, senolytic intervention with disatinib and quercetin showed striking improvement in pulmonary and physiological functions [21].”
BackgroundCellular senescence in neurodegenerative diseases
Zhang, P., & Sung, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822514-1.00012-2 · Cited by 10
Targeting cellular senescence: A promising approach in respiratory diseases
Sugimoto, M. (2023) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.14653 · Cited by 9
DEC1 is involved in circadian rhythm disruption-exacerbated pulmonary fibrosis
Chen, S.-J., Yu, F., Feng, X. Y., Li, Q., Jiang, Y.-H., Zhao, L., Cheng, P., Wang, M., Song, L., Liang, L., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01614-w · Cited by 9
“So, stress-induced premature senescence of ATII cells and chronic SASP are key regulators of pulmonary fibrosis [36, 37].”
BackgroundHe, B., Zeng, Q., Tian, Y., Luo, Y., Liao, M., Huang, W., Wu, B., Luo, Z., Huang, X., Liu, W. Q., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12071436 · Cited by 10
“Senescent fibroblasts persist in the lung tissues of those with pulmonary fibrosis diseases [8–10], and these senescent fibroblasts are usually accompanied with cell cycle inhibition, telomere shortening, senescence-associated secretory phenotypes (SASPs), and mitochondrial dysfunction, which are…”
BackgroundHigh-throughput single telomere analysis using DNA microarray and fluorescent in situ hybridization
Zheng, Y., Wu, X., Williams, M., Verhulst, S., Lin, J., Takahashi, Y., Ma, J., & Wang, Y. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae812 · Cited by 9
Virus‐Induced Cellular Senescence Causes Pulmonary Sequelae Post‐Influenza Infection
Lipskaia, L., Delval, L., Sencio, V., Born, E., Heumel, S., Houssaini, A., Valentin, C., Raviola, S., Deruyter, L., Angulo, F. S., et al. (2025) · Aging Cell · doi:10.1111/acel.70140 · Cited by 11
“Previous studies have shown that the elimination of senescent cells can protect against lung emphysema or pulmonary fibrosis in relevant (non-infectious) animal models (Lehmann et al. 2017; Schafer et al. 2017; Kaur et al. 2023).”
Zhou, J., An, X., Xia, X., Xiao, W., Ding, D., Li, W., & Huang, Q. (2025) · European journal of medical research · doi:10.1186/s40001-025-02755-5 · Cited by 17
Babaei‐Jadidi, R., Clements, D., Wu, Y., Chen, K., Miller, S., Platé, M., Lim, K., Rue, R. W., Krymskaya, V. P., Chambers, R. C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64036-3 · Cited by 13
Mikawa, T., Kameda, M., Ikari, S., Shibata, E., Liu, S., Miyagawa, S., Ono, K., Ito, T., Yoshizawa, A., Sugimoto, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02502-6 · Cited by 15
Dermatomyositis is characterized by JAK1-mediated monocyte-driven vasculopathy and inflammation
Osborne, G. A., Zhang, L., Ma, F., Gharaee‐Kermani, M., Turnier, J. L., Victory, A., Hurst, A., Xu, B., Pedersen, E. A., Wasikowski, R., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.aea9007 · Cited by 12
Florian-Rodriguez, M. E., Hare, A. M., Gaddam, N. G., Shi, H., Keller, P., & Word, R. A. (2022) · Urogynecology · doi:10.1097/spv.0000000000001131 · Cited by 10
Li, Y., Wang, Q., Li, J., Li, A., Wang, Q., Zhang, Q., & Chen, Y. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2022.12.004 · Cited by 9
Deng, E. Z., Fleishman, R. H., Xie, Z., Marino, G. B., Clarke, D. J. B., & Ma’ayan, A. (2023) · Aging Cell · doi:10.1111/acel.13809 · Cited by 7
The Role of Autophagy and Apoptosis in Affected Skin and Lungs in Patients with Systemic Sclerosis
Spasovski, V., Andjelković, M., Parezanovic, M., Komazec, J., Ugrin, M., Klaassen, K., & Stojiljković, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311212 · Cited by 8
“Two processes that seem to have a crucial role in the development of UIP/IPF are senescence and autophagy [97,98].”
BackgroundMa, M., Gao, Y., Qiu, X., Gui, X., Tian, Y., Tian, M., Albertson, T. E., Kishaba, T., Tanino, Y., Sakairi, Y., et al. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-815 · Cited by 7
“The expression of protein senescence markers, including p16, p21, and p53, are significantly increased in IPF lung tissues, especially in AECs (14,41).”
Sato, S., Ogawa, Y., Shimizu, E., Asai, K., Okazaki, T., Rusch, R., Hirayama, M., Shimmura, S., Negishi, K., & Tsubota, K. (2024) · The Ocular Surface · doi:10.1016/j.jtos.2024.03.006 · Cited by 11
Metadata
- Authors
- Schafer, M. J., White, T. A., Iijima, K., Haak, A. J., Ligresti, G., Atkinson, E. J., Oberg, A. L., Birch, J., Salmonowicz, H., Zhu, Y., Mazula, D. L., Brooks, R. W., Fuhrmann-Stroissnigg, H., Pirtskhalava, T., Prakash, Y. S., Tchkonia, T., Robbins, P. D., Aubry, M. C., Passos, J. F., Kirkland, J. L., Tschumperlin, D. J., Kita, H., & LeBrasseur, N. K.
- Affiliations
- Mayo Clinic (US)
- Newcastle University (GB)
- Scripps Research Institute (US)
- Corresponding author
- LeBrasseur, Nathan K.
- ORCID
- Venue
- Nature Communications
- Published
- 2017-02-23
- Volume
- 8
- Issue
- 1
- Pages
- 14532-14532
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5331226
- OpenAlex
- W2591114726
- Cited by
- 1,613
- References
- 52
- Citations by year
- 2026: 195 · 2025: 205 · 2024: 193 · 2023: 193 · 2022: 192 · 2021: 181 · 2020: 176 · 2019: 128 · 2018: 107 · 2017: 42
- FWCI
- 91.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- Mayo Clinic (UL1-TR000135)
- Glenn Foundation for Medical Research
- Louisiana Transportation Research Center
- Georgia Clinical and Translational Science Alliance (UL1 TR000135)
- Noaber Foundation
- Fondation pour la Recherche Médicale
- National Institutes of Health (UL1TR000135, 2r01hl092961-13)
- Directorate for Biological Sciences
- Biotechnology and Biological Sciences Research Council (BB/K017314/1, BB/H022384/1)
- National Institute on Aging (R01AG053832, R01AG013925, R37AG013925)
- National Heart, Lung, and Blood Institute (R01-HL-092961)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- cellular senescence, idiopathic pulmonary fibrosis, senolytics, senescence-associated secretory phenotype, senescent fibroblasts, p16, bleomycin-induced lung injury, interstitial pulmonary fibrosis, suicide gene therapy, lung function
- MeSH terms
- Animals, Bleomycin, Fibroblasts, Humans, Lung, Male, Biomarkers, Cellular Senescence, Cyclin-Dependent Kinase Inhibitor p16, Proteome, Mice, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.